Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer

Table 1

Comparison of general data of the four groups of patients (‾x ± s).

Groups	Gender (male/female) (case)	Mean age (year)	Mean course of disease (months)	Stage (case)
				IIIa	IIIb	IIIc	IV
Control group	35/16	48.62 ± 6.87	4.61 ± 1.53	11	20	11	9
Study I group	32/19	51.04 ± 7.98	5.02 ± 2.31	10	22	10	9
Study II group	36/15	50.04 ± 5.34	4.87 ± 2.75	11	21	9	10
Study III group	34/17	49.77 ± 8.23	4.91 ± 1.83	12	19	10	10
X^2/F	0.482	0.975	0.331	0.232	0.408	0.249	0.129
	0.546	0.406	0.803	0.975	0.939	0.969	0.988